A tiny particle developed by researchers at the University of New South Wales in Australia could boost the effectiveness of neuroblastoma chemotherapy.
Advanced Cancer Therapeutics will pursue further preclinical development of a possible brain cancer treatment, backed by a new NIH grant.
Stemline Therapeutics delayed its initial public offering this week, as another biotech faces a rocky road from private to public status. The oncology drug specialist planned to raise $42 million in an IPO this week at a price of $11 to $13 per share, the Nasdaq reported Tuesday, selling itself as a leader in the development of drugs that home in on cancer stem cells that are implicated in cancer recurrence.
Researchers at Northwestern Brain Tumor Institute are working to figure out whether a vaccine made from a patient's own white blood cells can be used to attack cancers by slowing the growth of tumors.
Medulloblastomas are particularly nasty cancerous brain tumors, and they are among the most common in kids. But now researchers from Dana-Farber/Children's Hospital Cancer Center, Boston Children's Hospital, Stanford University School of Medicine and elsewhere have taken a big step toward deciphering how to treat them. They've been able to link mutations in specific genes to each of four recognized subtypes of the cancer.
A new drug, given along with chemotherapy, has helped beat back neuroblastoma tumors in mice. Buffalo, NY-based Cleveland BioLabs ($CBLI) and its Russian subsidiary Incuron are developing the compound. They broke the news at last week's Advances in Neuroblastoma Research Association 2012 meeting in Toronto.
Another site in the U.S. has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme.
A team at Brigham and Women's Hospital in Boston thinks it has stumbled upon a game-changing way to eliminate the need for surgery in suspected brain tumor patients.
A discovery by researchers at Rice University and the Methodist Neurological Institute could help deliver chemo drugs to brain tumor cells.
A drug made in part from the Chinese medicinal herb Angelica sinensis doubled the life expectancy of mice with a rare brain tumor.